Researchers examined the immunogenicity and safety of an investigational mRNA-1083 vaccine against seasonal influenza and SARS-CoV-2 in adults aged 50 years and older in a trial conducted across 146 United States sites.

The head of the US Food and Drug Administration reiterated that the agency is applying a more skeptical approach to this year’s round of COVID-19 vaccine boosters.

Nearly 72% of infants were found to be immunized against respiratory syncytial virus.